Arrive AI Inc Dossier - Source-backed chat

Arrive AI Inc

ARAINASDAQ

SectorIndustrials

IndustryAir Freight and Logistics

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.22Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $11.3M

Enterprise Value $15.9M

Shares Outstanding 44.7M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Arrive AI Inc. (NASDAQ: ARAI) is a developmental-stage technology company building the physical and digital infrastructure for autonomous last-mile logistics. Centered on its patented 'Arrive Points' smart mailboxes, the company aims to establish a carrier-neutral network that facilitates secure, asynchronous exchanges of goods between people, drones, and ground robots. While the company possesses a robust global patent portfolio (over 80 patents) and has initiated early pilot deployments (such as with Hancock Health), it remains virtually pre-revenue, generating only $14,925 in Q1 2026. Arrive AI faces severe financial and execution risks, including a high cash burn rate, substantial dilution from convertible note conversions, and ongoing Nasdaq listing compliance challenges regarding its minimum bid price and market value of listed securities. Consequently, a Hold recommendation is advised until commercial contracts scale and the capital structure stabilizes.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$1.00

High · most bullish analyst$1.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.1030%

Pilot projects fail to transition into paying commercial contracts, leaving the company with minimal revenue. The company is unable to resolve its Nasdaq minimum bid price or MVLS deficiencies, leading to a delisting from the Nasdaq Global Market. Severe dilution from the Streeterville Capital conversions and the Maxim Group ATM program decimates shareholder value, and the company faces a liquidity crisis as its cash runway expires.

Base CaseCentral scenario

$5.0050%

Arrive AI continues to execute on its product roadmap, deploying AP3 platform enhancements in July 2026 and achieving broader commercial availability in October 2026. Revenue grows gradually from early commercial rollouts, but the company remains unprofitable over the next 2-3 years. Funding is maintained through highly dilutive ATM equity sales and convertible note conversions, keeping the company afloat but capping per-share upside.

Bull CaseUpside scenario

$12.0020%

Widespread regulatory approval of autonomous drone delivery (e.g., FAA Part 108) accelerates the adoption of carrier-neutral smart mailboxes. Arrive AI successfully converts its pilot pipeline into high-margin, recurring Mailbox-as-a-Service (MaaS) subscription revenue. The company leverages its extensive patent portfolio to secure strategic partnerships or becomes an attractive acquisition target for major logistics giants like Amazon, FedEx, or UPS.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong intellectual property portfolio with over 80 patents globally covering autonomous delivery reception and climate-controlled smart mailboxes.
First-mover advantage in establishing carrier-neutral physical endpoints for autonomous delivery networks.
Early pilot deployments and commercial contracts, such as the expansion at Hancock Health and partnerships with specialty pharmaceutical logistics.

Key Investment Risks

Extremely early commercial stage with minimal revenue ($14,925 in Q1 2026) and substantial net losses ($6.37M in Q1 2026).
High cash burn rate and limited cash runway (approximately 8 months as of March 31, 2026) creating going concern uncertainty.
Severe dilution risk from ongoing convertible note conversions and the newly established $14.97M at-the-market equity program.
Regulatory and compliance risks, including active Nasdaq deficiencies for minimum bid price and market value of listed securities.

Thesis Invalidation Triggers

Delisting of ARAI common stock from the Nasdaq Global Market.
Failure to deploy the AP3 platform enhancements by the end of 2026.
Inability to secure additional financing or a material breach of the Streeterville Capital standstill agreement.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.